A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
NCT02251288
Completed
A phase I prospective, randomized study in healthy adult subjects at a single center. Adult subjects age 18 to 47 years and meeting all enrollment criteria will choose to participate as subjects who receive inactivated vaccine followed by a live vaccine boost at 4 weeks (Group 1), 12 weeks (Group 2), or 24 weeks (Group 3), or to be in an observational group (Group 4) which will not be scheduled for a booster dose but may serve as a roll-over group for subjects who withdraw prior to the second va... Read More
Gender:
ALL
Ages:
Between 18 years and 47 years
Trial Updated:
01/23/2020
Locations: University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York
Conditions: Avian Influenza, Immunisation
Register for Updates
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
NCT00148941
Completed
The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV vaccine with respect to immunogenicity and safety compared to the control vaccines (separate injections of GSK Biologicals' DTaP vaccine \[Infanrix\] and Aventis Pasteur's IPV vaccine \[IPOL\]) when administered as a 5th dose of DTaP and a 4th dose of inactivated poliovirus... Read More
Gender:
ALL
Ages:
Between 4 years and 6 years
Trial Updated:
01/22/2020
Locations: GSK Investigational Site, Little Rock, Arkansas +23 locations
Conditions: Tetanus, Acellular Pertussis, Diphtheria
Register for Updates
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients
NCT02018419
Withdrawn
This phase I/II study is designed to compare different treatment schedules of a personalized anti-cancer vaccine protocol which combines the cryoablation of a selected metastatic lesion with intra-tumor immunotherapy. The cryoablation causes the tumor to release tumor-specific antigens into the surrounding environment. The injection of bioengineered allogeneic immune cells, AlloStim(TM), into the lesion is designed to modulate the immune response and educate the immune system to kill other tumor... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
01/17/2020
Locations: Medical Oncology Associates of San Diego, San Diego, California
Conditions: Metastatic Breast Cancer
Register for Updates
Traveler's Diarrhea (TD) Automated Process
NCT00751777
Completed
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
01/16/2020
Locations: Solano Clinical Research, Vallejo, California +2 locations
Conditions: Prevention of Travelers' Diarrhea
Register for Updates
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01239875
Completed
RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tumor cells. PURPOSE: This clinical trial studies giving vaccine therapy together with or without cryosurgery in treating patients with B-cell Non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/13/2020
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma, Adult Diffuse Small Cleaved Cell Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Adult Immunoblastic Large Cell Lymphoma, Adult Lymphoblastic Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia With Nodal Disease
Register for Updates
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00490529
Completed
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
01/08/2020
Locations: Stanford University Medical Center, Stanford, California
Conditions: Lymphoma, Mantle-Cell
Register for Updates
Immunologic Response to Influenza Vaccination in Children and Adolescents
NCT03614975
Completed
The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-20 years of age. This is a randomized controlled trial (RCT), that will assess immune response in 120 participants (60 per vaccine arm) pre- and post-vaccination to Flucelvax (egg-free inactivated flu shot) and Fluzone (egg-based inactivated flu shot).
Gender:
ALL
Ages:
Between 4 years and 20 years
Trial Updated:
01/07/2020
Locations: General Academic Pediatrics, Pittsburgh, Pennsylvania +1 locations
Conditions: Influenza, Human, Immune Response
Register for Updates
IM Recombinant Ricin Toxin Vaccine (RVEc) - 3-Dose Primary Series With Boost
NCT02385825
Withdrawn
This study seeks to determine the safety and immunogenicity of a series of 3 primary vaccinations and a booster vaccination of Recombinant ricin toxin A-chain 1-33/44-198 (rRTA 1-33/44-198) vaccine (RVEc) at 10, 50, or 75 μg IM. This study is evaluating if RVEc will display an acceptable safety profile as determined by adverse event (AE) data and if RVEc will elicit anti-ricin antibody titers and ricin toxin-neutralizing antibodies in vaccine recipients.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/30/2019
Locations: Department of Clinical Research, USAMRIID, Fort Deterick, Maryland
Conditions: Ricin Poisoning
Register for Updates
ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ - 3-Dose Primary Series With Boost
NCT02386150
Withdrawn
This study seeks to determine the safety and immunogenicity of a series of 3 primary vaccinations and a booster vaccination of Recombinant ricin toxin A-chain 1-33/44-198 (rRTA 1-33/44-198) vaccine (RVEc) at 10 or 20 μg intradermally (ID). This study is evaluating if RVEc will display an acceptable safety profile as determined by adverse event (AE) data and if RVEc will elicit anti-ricin antibody titers and ricin toxin-neutralizing antibodies in vaccine recipients.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/30/2019
Locations: Department of Clinical Research, USAMRIID, Fort Deterick, Maryland
Conditions: Ricin Poisoning
Register for Updates
Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
NCT01317667
Completed
This study is a Phase 1, escalating, multiple-dose, single-center study to evaluate the safety and immunogenicity of the RVEc vaccine. The two principal hypotheses to be tested are: RVEc vaccine will display an acceptable safety profile as determined by adverse event data and RVEc vaccine will elicit ELISA immunoglobulin G (IgG) titers greater than or equal to 1:500 and toxin-neutralizing antibody (TNA) anti-ricin toxin-neutralizing antibody titers greater than or equal to 1:50 in vaccine recip... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/30/2019
Locations: Department of Clinical Research, U.S. Army Medical Research Institute of Infectious Diseases, Fort Deterick, Maryland
Conditions: Ricin
Register for Updates
Safety and Immunogenicity of Q Fever Vaccine
NCT02092142
Withdrawn
The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2019
Locations: Special Immunizations Program, Division of Medicine, USAMRIID, Fort Deterick, Maryland
Conditions: Q Fever
Register for Updates
Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab
NCT03056924
Completed
Patients with Crohn's disease (CD) and ulcerative colitis (UC) are often treated with medications that suppress the immune system. These patients are therefore at increased risk for developing infections, such as influenza, pneumonia, and hepatitis B, which may be prevented by vaccination. While awareness is increasing among gastroenterologists of the importance of vaccinations in the IBD patient, there continues to be some question of the effectiveness of vaccination in immunosuppressed patient... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/27/2019
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Inflammatory Bowel Diseases
Register for Updates